КОРНБЛАТТ Брайн (US),КОРНБЛАТТ Грейс (US),БЖЕЛЯНСКИЙ Антон (US),ХЕНДЕРСОН Роберт В. (US)
申请号：
RU2015103499
公开号：
RU2015103499A
申请日:
2013.07.03
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. An oral composition comprising: a sulforaphane precursor； an enzyme capable of converting a sulforaphane precursor to sulforaphane； an enzyme potentiator and milk thistle extract or powder. 2. A composition for oral administration according to claim 1, wherein the sulforaphane precursor contains glucoraphanin. The oral composition of claim 1, wherein the enzyme capable of converting the sulforaphane precursor to sulforaphane contains myrosinase. A composition for oral administration according to claim 1, wherein the enzyme potentiator contains ascorbic acid. The oral composition of claim 1, wherein the composition comprises an enteric tablet or capsule. The oral composition according to claim 1, further comprising one or more additional components selected from the group consisting of: quercetin, amino carbohydrate, glycosaminoglycan, unsaponifiables based on avocados and soybeans, vitamin, coffee tree fruits, magnesium, silymarin, proanthocyanidins , ursolic acid, curcumin, phytosterols and phiostanols. 7. A composition for oral administration according to claim 1, comprising glucoraphanin, myrosinase, ascorbic acid and milk thistle extract. A composition for oral administration according to claim 1, wherein the composition comprises an extract or broccoli powder. A method for treating, preventing, reducing the frequency, reducing symptoms and reducing repeated relapses of colorectal cancer or colon cancer, comprising administering to a subject in need thereof a sulforaphane precursor； an enzyme capable of converting a sulforaphane precursor to sulforaphane；1. Композиция для перорального введения, содержащая:предшественник сульфорафана；фермент, способный превращать предшественник сульфорафана в сульфорафан；потенциатор фермента иэкстракт или порошок молочного чертополоха.2. Композиция для перорального введения по п. 1, в которой предшественник сульфорафана содержит глюкорафанин.3. Композиция для перорального введения по п. 1, в которой фермент, способный превраща
